For patients seeking sustainable weight loss, this shift has raised an important question: What happens when medication access changes or ends entirely
Back McIntyre, N, Holdsworth, CD, Turner, DA (4 July 1964) 'New interpretation of oral glucose tolerance', The Lancet , 2, 2021
Epub 2013 Feb 27
p = 0.03) (Fig
In a pooled analysis of phase 2 and 3a clinical trials of liraglutide for weight management, when administered once daily at a dose of 3.0 mg caused no major concerns regarding its neuropsychiatric safety [123]
The main side effects are gastrointestinal, specifically flatulence and diarrhea, resulting from undigested starches reaching the large intestine